CA3040916C - Method of manufacturing and the use of cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury - Google Patents
Method of manufacturing and the use of cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury Download PDFInfo
- Publication number
- CA3040916C CA3040916C CA3040916A CA3040916A CA3040916C CA 3040916 C CA3040916 C CA 3040916C CA 3040916 A CA3040916 A CA 3040916A CA 3040916 A CA3040916 A CA 3040916A CA 3040916 C CA3040916 C CA 3040916C
- Authority
- CA
- Canada
- Prior art keywords
- cordyceps cicadae
- mycelia
- medicine
- acute lung
- lung injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001625026 Cordyceps cicadae Species 0.000 title claims abstract description 84
- 206010069351 acute lung injury Diseases 0.000 title claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 239000013543 active substance Substances 0.000 title abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims description 32
- 206010035664 Pneumonia Diseases 0.000 claims description 21
- 230000008595 infiltration Effects 0.000 claims description 20
- 238000001764 infiltration Methods 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 18
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 210000000440 neutrophil Anatomy 0.000 claims description 13
- 210000001539 phagocyte Anatomy 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 description 68
- 229920006008 lipopolysaccharide Polymers 0.000 description 50
- 239000000203 mixture Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 10
- 239000007928 intraperitoneal injection Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000004859 alveolar capillary barrier Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A method for manufacturing Cordyceps cicadae mycelia active substance for preventing and/or treating acute lung injury is provided. The method comprises the following steps: (a) culturing a Cordyceps cicadae mycelia in a plate media between 15 to 30°C for 1 to 2 weeks; (b) inoculating the mycelia of step (a) to a flask and culturing it between 15 to 30°C at a pH of 2 to 6 for 3 to 14 days; (c) inoculating the mycelia of step (b) to a fermenter tank and culturing it between 15 to 30°C at a pH of 2 to 6 for 3 to 21 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing said Cordyceps cicadae mycelia active substance.
Description
Method of manufacturing and the use of Cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury BACKGROUND
Technical Field [0001] The present invention relates to a Cordyceps cicadae mycelia active substance, a method for manufacturing said Cordyceps cicadae mycelia active substance, and the use thereof. In particular, the present invention relates to a Cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury, a method for manufacturing said Cordyceps cicadae mycelia active substance, and the use thereof in food or pharmaceuticals.
Description of Related Art
Technical Field [0001] The present invention relates to a Cordyceps cicadae mycelia active substance, a method for manufacturing said Cordyceps cicadae mycelia active substance, and the use thereof. In particular, the present invention relates to a Cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury, a method for manufacturing said Cordyceps cicadae mycelia active substance, and the use thereof in food or pharmaceuticals.
Description of Related Art
[0002] Among the ten leading causes of death in 2017 according to Taiwan's Ministry of Health and Welfare, four of them are closely associated with lung inflammation, namely, malignant neoplasms (ranked no. 1) including cancers of trachea, bronchus and lung, pneumonia (ranked no. 3), and chronic lower respiratory diseases (ranked no. 7).
[0003] Among the ten leading causes of death in the United States, three of them are associated with lung diseases, namely, lung cancer and bronchogenic carcinoma, chronic respiratory diseases, influenza, and pneumonia. Statistical analyses further showed that in the U.S., 79 out of 100,000 were inflicted with acute lung injury (ALI), 59 out of 100,000 were with acute respiratory distress syndrome (ARDS), and that 43% of all deaths were caused by ALI/ARDS, that is, 75,000 deaths per year. As air pollution levels continue to increase and life expectancy continues to rise every year, it is estimated that the incidence of ALI/ARDS in the U.S. will at least double in 25 years.
[0004] ALT and ARDS (more severe than ALI) are acute inflammatory lung diseases that are frequently seen clinically, both of which may cause respiratory failure and may be fatal. They are also associated with many respiratory diseases.
[0005] ALI-causing risk factors fall into two major groups: direct and indirect risk factors. Direct risk factors are those which originate in the lungs, such as infective pneumonia caused by bacteria or viruses, aspiration of gastric acid or foreign objects, or lung contusion. On the other hand, indirect risk factors are those which do not originate in the lungs, such as sepsis, chronic use of alcohol and drugs, or transfusion of artificial blood plasma.
Bacterial infection is one of the above-mentioned major risk factors, an example being infection by Gram-negative bacteria whose envelope is mainly composed of endotoxins, also known as lipopolysaccharide (LPS).
Bacterial infection is one of the above-mentioned major risk factors, an example being infection by Gram-negative bacteria whose envelope is mainly composed of endotoxins, also known as lipopolysaccharide (LPS).
[0006] Due to the complex mechanism and high case fatality rate of ALT, there is still a lack of clinically effective drugs that can be used to manage ALI's case fatality rate, while common treatments of ALT include mechanical ventilation, beta-2 adrenergic receptor agonist, anticoagulation, thrombolysis, surfactant therapy, and surgery. Therefore, research on effective treatments of ALT remains essential for development.
[0007] Cordyceps cicadae, also known as chong hua, tit chan hua, hil chan, and chan yong cao, is a flower bud-shaped stroma formed with strains at the front end of a cicada larva, which is parasitized by a genus of Cordyceps, a family of Clavicipitaceae fungal spores, and turned into a bacteria-carrying carcass. It is written in Compendium of Materia Medica, Herbology of Classified Syndromes and Zhong hua yao heti that Cordyceps cicadae is mainly used for treating morbid night crying of babies, palpitation, and malaria, as well as dispelling wind and heat from the body and relieving convulsion. It has been found through component analysis that natural Cordyceps cicadae fruit bodies and Ophiocordyceps sinensis are composed in a similar way.
[0008] Recent pharmaceutical research has found that Cordyceps cicadae is bioactive with effects of immune response regulation, anti-oxidation, anti-inflammation, neuroprotection, and anti-cancer. However, there has been no research done on improving ALI using Cordyceps cicadae mycelia.
SUMMARY
SUMMARY
[0009] Provided herein is a Cordyceps cicadae mycelia active substance and a method of manufacturing said Cordyceps cicadae mycelia active substance, which can be used for manufacturing a composition effective in preventing and/or improving acute lung injury. Compared to conventional drugs and treatments, the method for manufacturing the fermentation liquid of the Cordyceps cicadae mycelia active substance disclosed herein is safer and simpler, and the Cordyceps cicadae mycelia active substance manufactured is more natural and safer, as well as effective in improving ALT.
[0010] According to one embodiment of the present invention, a method is provided for manufacturing a Cordyceps cicadae mycelia active substance for improving AL!. The method comprises the following steps:
[0011] (a) culturing Cordyceps cicadae mycelia in a plate medium between 15 and 30 C for 1 to 2 weeks;
[0012] (b) inoculating the Cordyceps cicadae mycelia of step (a) to a flask and culturing the mycelia between 15 and 30 C and at a pH of 2 to 6 for 3 to 14 days; and
[0013] (c) inoculating the Cordyceps cicadae mycelia of step (b) to a fermenter tank and culturing the mycelia by stirring between 15 and 30 C
and at a pH of 2 to 6 for 3 to 21 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing Cordyceps cicadae mycelia active substance.
and at a pH of 2 to 6 for 3 to 21 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing Cordyceps cicadae mycelia active substance.
[0014] In one embodiment, the method for manufacturing a Cordyceps cicadae mycelia active substance further includes steps of (d): freeze-drying the Cordyceps cicadae mycelium fermentation liquid and grinding the freeze-dried product, so as to obtain a Cordyceps cicadae mycelium powder containing Cordyceps cicadae mycelia active substance.
[0015] In one embodiment, a gas is further fed into the fermenter tank of step (c), and the gas comprises air, oxygen, carbon dioxide, helium or a combination thereof; the pressure of the fermenter tank is 0.5 to 1.0 kg/cm2, and a gas flow rate is 0.01 to 1.5 VVM.
[0016] In another embodiment of the present invention, a Cordyceps cicadae mycelia active substance is provided, which is manufactured using the said method.
[0017] In yet another embodiment of the present invention, a composition for preventing and/or improving acute lung injury is provided, which comprises said Cordyceps cicadae mycelia active substance, and a pharmaceutically acceptable carrier, excipient, diluent or adjuvant.
[0018] In yet another embodiment of the present invention, A use of said Cordycep cicadae mycelia active substance is provided, which is used for manufacturing a composition for preventing and/or improving acute lung injury.
[0019] In one embodiment, improving acute lung injury as mentioned above includes alleviating pathological symptoms of lung inflammation.
[0020] In one embodiment, alleviating pathological symptoms of lung inflammation as mentioned above includes restoring the integrity of damaged or fused alveoli.
[0021] In one embodiment, improving acute lung injury as mentioned above includes reducing protein leakage response.
[0022] In one embodiment, improving acute lung injury as mentioned above includes reducing the level of infiltration in inflamed cells.
[0023] In one embodiment, said inflamed cells includes leukocytes, phagocytes and/or neutrophils.
[0024] For the purpose of further illustrating the above and other aspects of the present invention, several exemplary embodiments will be described with reference to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Fig. 1 shows that pathological conditions of ALI can be improved by administering with freeze-dried powder of Cordyceps cicadae mycelia by intraperitoneal injection and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
[0026] Fig. 2 shows that ALI-caused damage of alveolar-capillary barrier can be improved by administering with freeze-dried powder of Cordyceps cicadae mycelia by intraperitoneal injection and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
[0027] Fig. 3 shows that ALI-caused infiltration in (A) leukocytes, (B) phagocytes and (C) neutrophils can be improved by administering with freeze-dried powder of Cordyceps cicadae mycelia by intraperitoneal injection and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
[0028] Fig.
4 shows that pathological conditions of ALT can be improved by administering with freeze-dried powder of Cordyceps cicadae mycelia orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
4 shows that pathological conditions of ALT can be improved by administering with freeze-dried powder of Cordyceps cicadae mycelia orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
[0029] Fig.
5 shows that ALT-caused damage of the alveolar-capillary barrier can be improved by administering freeze-dried powder of Cordyceps cicadae mycelia orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
5 shows that ALT-caused damage of the alveolar-capillary barrier can be improved by administering freeze-dried powder of Cordyceps cicadae mycelia orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
[0030] Fig.
6 shows that ALT-caused infiltration in (A) leukocytes, (B) phagocytes and (C) neutrophils can be improved by administering freeze-dried powder of Cordyceps cicadae mycelia by orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
DETAILED DESCRIPTION
Example 1: Culturing Cordyceps cicadae mycelia
6 shows that ALT-caused infiltration in (A) leukocytes, (B) phagocytes and (C) neutrophils can be improved by administering freeze-dried powder of Cordyceps cicadae mycelia by orally and then administering endotoxins by nasal inhalation to induce acute lung inflammation.
DETAILED DESCRIPTION
Example 1: Culturing Cordyceps cicadae mycelia
[0031]
Cordyceps cicadae mycelia of the present invention are obtained through the following steps: gathering a natural Taiwanese Cordyceps cicadae strain, separating its mycelium from the fruit body and storing the mycelia in a plate medium by subculture. The gene sequence of the strain is confirmed as Cordyceps cicadae by Taiwan Food Industry Research and Development Institute. This strain of Cordyceps cicadae strains are now publicly deposited in the Bioresource Collection and Research Center (BCRC) of Taiwan Food Industry Research and Development Institute with BCRC number: MU30106, but the Cordyceps cicadae mycelia active substance of the present invention is not limited to the substance prepared from such strains.
Cordyceps cicadae mycelia of the present invention are obtained through the following steps: gathering a natural Taiwanese Cordyceps cicadae strain, separating its mycelium from the fruit body and storing the mycelia in a plate medium by subculture. The gene sequence of the strain is confirmed as Cordyceps cicadae by Taiwan Food Industry Research and Development Institute. This strain of Cordyceps cicadae strains are now publicly deposited in the Bioresource Collection and Research Center (BCRC) of Taiwan Food Industry Research and Development Institute with BCRC number: MU30106, but the Cordyceps cicadae mycelia active substance of the present invention is not limited to the substance prepared from such strains.
[0032] (1) Plate culture: A Cordyceps cicadae mycelium was inoculated onto a plate medium and cultured between 15 to 30 C for 1 to 2 weeks (at 25 C for 7 days in this example). The recipe for the medium may include Potato Dextrose Agar (PDA), carbon sources and nitrogen sources, and is not specifically limited.
[0033] (2) Culture in a flask: Cordyceps cicadae mycelia were scraped from the plate of step (1) and inoculated to a flask. The culture was grown at 110 to 130 rpm in a shaker incubator between 15 to 30 C and at a pH of 2 to 6 for 3 to 14 days (at 120 rpm, 25 C and pH 5 for 7 days in this example).
The recipe of the shaking culture was shown in Table 1:
The recipe of the shaking culture was shown in Table 1:
[0034] Table 1: Recipe for the culture medium Amount used in this Preferred range of Ingredient example (weight%) amount (weight%) Mixed carbon and nitrogen 1 0.01 to 5 sources Carbohydrates 2.5 0.01 to 10 Yeast or malt extract 0.8 0.001 to 2 Animal and plant proteins and 0.5 0.01 to 2 hydrolysates thereof Inorganic salts 0.05 0.0001 to 0.05
[0035] Among the above ingredients, mixed carbon and nitrogen sources can be cereals (such as wheat flour) or legumes (such as soya bean powder, mung bean powder, Glycine max powder or cinnamon powder);
carbohydrates can be glucose, fructose, maltose, sucrose and the like; and inorganic salts can be magnesium sulfate, dipotassium phosphate, potassium dihydrogen phosphate, ferric sulfate and the like. It should be noted that the recipe as shown in Table 1 is only exemplary, and that the ingredients therein are not specifically limited and can be adjusted according to actual needs or used in combination with commercially available culture media.
carbohydrates can be glucose, fructose, maltose, sucrose and the like; and inorganic salts can be magnesium sulfate, dipotassium phosphate, potassium dihydrogen phosphate, ferric sulfate and the like. It should be noted that the recipe as shown in Table 1 is only exemplary, and that the ingredients therein are not specifically limited and can be adjusted according to actual needs or used in combination with commercially available culture media.
[0036] (3) Culture in a fermenter tank: The culture in the flask of step (2) was further inoculated into a fermenter tank and was stirred between 50 to 150 rpm in temperature between 15 to 30 C, the tank pressure between 0.5 to 1.0 kg/cm2 and the pH between 2 to 6. Meanwhile, gas was fed into the tank at a gas flow rate of 0.1 to 1.0 VVM. The resulting culture was incubated for 3 to 21 days to obtain a Cordyceps cicadae mycelium fermentation liquid (in this example, the culture conditions were 25 C, 0.5 kg/cm2, pH 5, 80 rpm and 1.0 VVM (air) for 14 days). The medium used in the fermenter tank may contain either the same recipe as the culture in a flask of step (2) or other appropriate media (the same recipe as step (2) was used in this example). This Cordyceps cicadae mycelia fermentation liquid includes Cordyceps cicadae mycelia active substance of the present invention. The Cordyceps cicadae mycelium fermentation liquid can be further freeze-dried to obtain a freeze-dried powder of Cordyceps cicadae mycelia. In this example, 100 L of Cordyceps cicadae mycelium fermentation liquid was freeze-dried into 3 kg of freeze-dried powder.
[0037] Cordyceps cicadae mycelia active substance can take various forms including Cordyceps cicadae mycelium fermentation liquid (strains and clarified liquid), a freeze-dried powder made from fermentation liquid, freeze-dried powder dissolved in a solvent, or in other formulations. In a preferred embodiment, the solvent for dissolving the freeze-dried powder is water, ethanol or a combination thereof In a preferred embodiment, the ratio of water to ethanol used as the solvent for dissolving the freeze-dried powder is 1:1. In the following Example 2, subsequent experiments and analyses were carried out with the Cordyceps cicadae mycelia active substance in the form of freeze-dried powder made from the fermentation liquid.
Example 2: Analyzing the use of Cordyceps cicadae mycelium freeze-dried powder to improve AL!
Example 2: Analyzing the use of Cordyceps cicadae mycelium freeze-dried powder to improve AL!
[0038] One of the major risk factors leading to ALT is Gram-negative bacterial infection, whose envelope is mainly composed of endotoxins, also known as lipopolysaccharide (LPS). Among various pathogens that cause ALT, LPS is widely considered as the most effective inducer of acute lung inflammation and the model of this induction is the closest to the acute inflammation that occurs clinically. Therefore, suppressing LPS-caused lung inflammation as well as immune-regulatory functions and mechanisms shall achieve the effect of improving ALT. There have been experiments in which animal models of endotoxin-induced ALT are employed. See Yunhe Fu et al.
(2017), Protective effect of TM6 on LPS-induced acute lung injury in mice, SCIENTIFIC REPORTS, 7:572. A mouse model of acute lung inflammation was established by LPS following the description in the above publication.
LPS 50 lig/ 20 [iL was administered intranasally to induce acute lung injury.
Analyses of changes in pulmonary pathology, total bronchoalveolar lavage fluid cell counts, protein concentration and various cytokines were then carried out, so as to assess the improvements that synthesized peptides, such as cell-permeable TIR domain-derived decoy peptide, had done to ALT. In this experiment, a mouse model of acute lung inflammation was also established using LPS. Analyses of changes in pulmonary pathology, total bronchoalveolar lavage fluid cell counts, protein concentration and various cytokines were then carried out to assess the improvements that the Cordyceps cicadae mycelia active substance had done to ALT.
(2017), Protective effect of TM6 on LPS-induced acute lung injury in mice, SCIENTIFIC REPORTS, 7:572. A mouse model of acute lung inflammation was established by LPS following the description in the above publication.
LPS 50 lig/ 20 [iL was administered intranasally to induce acute lung injury.
Analyses of changes in pulmonary pathology, total bronchoalveolar lavage fluid cell counts, protein concentration and various cytokines were then carried out, so as to assess the improvements that synthesized peptides, such as cell-permeable TIR domain-derived decoy peptide, had done to ALT. In this experiment, a mouse model of acute lung inflammation was also established using LPS. Analyses of changes in pulmonary pathology, total bronchoalveolar lavage fluid cell counts, protein concentration and various cytokines were then carried out to assess the improvements that the Cordyceps cicadae mycelia active substance had done to ALT.
[0039] BALB/c mice were used in this animal experiment and were divided into two major groups according to the route of administration:
intraperitoneal administration and oral administration. The two major groups were further divided into four groups: a control group to which no substance was administered (Control group), a group to which only LPS was administered (LPS group), a group to which both LPS and Cordyceps cicadae mycelia active substance were administered (CC mycelia group), and a positive control group to which both LPS and Dexamethasone were administered (DEX group), making a total of eight groups as shown in Table 2 below. There were six mice in each group with a total of 48 mice.
intraperitoneal administration and oral administration. The two major groups were further divided into four groups: a control group to which no substance was administered (Control group), a group to which only LPS was administered (LPS group), a group to which both LPS and Cordyceps cicadae mycelia active substance were administered (CC mycelia group), and a positive control group to which both LPS and Dexamethasone were administered (DEX group), making a total of eight groups as shown in Table 2 below. There were six mice in each group with a total of 48 mice.
[0040] Table 2: Group description Route of Group Substance administered administration Intraperitoneal Control N/A
LPS LPS
CC mycelia LPS + CC mycelia 0.25 mg/g weight of mice (6.25 mg of CC
mycelia for a mouse weighing 25g) DEX LPS + DEX 5 [ig/g weight of mice (125 pg of DEX for a mouse weighing 25g) Oral Control N/A
LPS LPS
CC mycelia LPS + CC mycelia 0.25 mg/g weight of mice (6.25 mg of CC
mycelia for a mouse weighing 25g) (once per day, three times in total) DEX LPS + DEX 5 p.g/g weight of mice (125 1.1g of DEX for a mouse weighing 25g) (once per day, three times in total)
LPS LPS
CC mycelia LPS + CC mycelia 0.25 mg/g weight of mice (6.25 mg of CC
mycelia for a mouse weighing 25g) DEX LPS + DEX 5 [ig/g weight of mice (125 pg of DEX for a mouse weighing 25g) Oral Control N/A
LPS LPS
CC mycelia LPS + CC mycelia 0.25 mg/g weight of mice (6.25 mg of CC
mycelia for a mouse weighing 25g) (once per day, three times in total) DEX LPS + DEX 5 p.g/g weight of mice (125 1.1g of DEX for a mouse weighing 25g) (once per day, three times in total)
[0041] In the intraperitoneal administration group, 20 1_, of LPS
was administered intranasally, and the concentration of LPS is 50 lig per mouse.
Mice were sacrificed 24 hours after administration, and samples were collected to be analyzed as described below. In the CC mycelia group, freeze-dried powder of Cordyceps cicadae mycelia was dissolved in a water/ethanol solvent at a ratio of 1:1. The resulting mixture was homogenized using sonication and used as the sample to be administered when it was confirmed that no precipitation was formed. 50 [EL of Cordyceps cicadae sample was administered intraperitoneally in mice and endotoxins (LPS) were administered intranasally 30 minutes after the administration of the Cordyceps cicadae sample using the same methods of administration and sacrifice as described above. In the DEX group, DEX was dissolved in saline and 50 lit of the resulting mixture was administered intraperitoneally in mice. Endotoxins (LPS) were administered intranasally 30 minutes after the administration of the DEX sample using the same methods of administration and sacrifice as described above.
was administered intranasally, and the concentration of LPS is 50 lig per mouse.
Mice were sacrificed 24 hours after administration, and samples were collected to be analyzed as described below. In the CC mycelia group, freeze-dried powder of Cordyceps cicadae mycelia was dissolved in a water/ethanol solvent at a ratio of 1:1. The resulting mixture was homogenized using sonication and used as the sample to be administered when it was confirmed that no precipitation was formed. 50 [EL of Cordyceps cicadae sample was administered intraperitoneally in mice and endotoxins (LPS) were administered intranasally 30 minutes after the administration of the Cordyceps cicadae sample using the same methods of administration and sacrifice as described above. In the DEX group, DEX was dissolved in saline and 50 lit of the resulting mixture was administered intraperitoneally in mice. Endotoxins (LPS) were administered intranasally 30 minutes after the administration of the DEX sample using the same methods of administration and sacrifice as described above.
[0042] In the oral administration group, 20 tiL of endotoxins (LPS) were administered intranasally, and the concentration of LPS is 50 i.tg per mouse. Mice were sacrificed 24 hours after administration, and samples were collected to be analyzed as described below. In the CC mycelia group, freeze-dried powder of Cordyceps cicadae mycelia was dissolved in a water/ethanol solvent at a ratio of 1:1. The resulting mixture was homogenized using sonication and used as the sample to be administered when it was confirmed that no precipitation was formed. 200 IlL of Cordyceps cicadae sample was administered in mice via a feeding tube for three days, once per day. Endotoxins (LPS) were administered intranasally three days after using the same methods of administration and sacrifice as described above. In the DEX group, DEX was dissolved in saline and the resulting mixture was administered in mice via a feeding tube, once per day.
Endotoxins (LPS) were administered intranasally three days after using the same methods of administration and sacrifice as described above.
Endotoxins (LPS) were administered intranasally three days after using the same methods of administration and sacrifice as described above.
[0043] Histopathological observation of lung tissues: the right lung of the mice that was not treated with alveolar lavage was taken out and fixated immediately in formalin. The fixated product was made into paraffin sections and dyed with conventional hematoxylin and eosin stain (H&E
stain). Histopathological changes were observed using light microscopy.
stain). Histopathological changes were observed using light microscopy.
[0044] Bronchoalveolar lavage (BAL): lung lavage was performed on the left lung of the mice with 1 mL of PBS three times using endotracheal intubation to wash out the contents in the alveolar cavity and to obtain BAL
fluid (BALF). The BALF was centrifuged and the precipitated cells were measured using differential blood cell count. The protein concentration in the supernatant was determined using Bradford protein assay.
fluid (BALF). The BALF was centrifuged and the precipitated cells were measured using differential blood cell count. The protein concentration in the supernatant was determined using Bradford protein assay.
[0045] Measurement of leukocytes count and type using flow cytometry: flow cytometry is a highly sensitive quantification method causing only small personal errors for determining white blood cell differentials in blood and BALF samples, based on antigens with specificity that are present on the surface of leukocytes. Targets of measurement include: (1) cell count in BALF; (2) leukocytes (CD45) count; (3) phagocytes (CD45+/CD1 lb) count; (4) neutrophils (CD45+/Ly6G+) count;
and (5) macrophage [(CD45+/CD1 lb+) - (CD45+/Ly6G+)] count.
and (5) macrophage [(CD45+/CD1 lb+) - (CD45+/Ly6G+)] count.
[0046] Statistical method: data are expressed as Mean + standard deviation (SD) and analyzed using one-way ANOVA. Group differences are analyzed using an LSD post-hoc test. Results with a p value less than 0.05 are considered statistically significant.
[0047] As shown in Fig. 1, intraperitoneal injection of freeze-dried powder of Cordyceps cicadae mycelia proved to be effective in improving inflammatory lung diseases. No significant changes were observed in the Control group with most alveolar structure remaining intact. In the LPS
group, pathological changes in the lung were clearly observed with the alveolar structure being damaged and fused. On the other hand, the lung diseases of the mice in the CC mycelia and DEX groups clearly improved.
group, pathological changes in the lung were clearly observed with the alveolar structure being damaged and fused. On the other hand, the lung diseases of the mice in the CC mycelia and DEX groups clearly improved.
[0048] After intraperitoneal injection, protein leakage response caused by endotoxin-induced lung inflammation was analyzed. It was found that freeze-dried powder of Cordyceps cicadae mycelia was effective in reducing protein leakage response, as shown in Fig. 2 and Table 3 below. # p <0.05 compared with Control group; * p <0.05 compared with LPS group.
[0049] Table 3: Protein leakage response after intraperitoneal injection Group Protein leakage (mg/mL) Control 2.87+1.02 LPS 9.93+1.52#
CC mycelia 5.39+1.27*
DEX 3.83+1.72*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 5.39+1.27*
DEX 3.83+1.72*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0050] After intraperitoneal injection, infiltration responses of (A) leukocytes (CD45) (B) phagocytes (CD45+/CD1 lb+) and (C) neutrophils (CD45+/Ly6G+) caused by endotoxin-induced lung inflammation were analyzed. It was found that freeze-dried powder of Cordyceps cicadae mycelia was effective in reducing infiltration response of leukocytes, phagocytes, and neutrophils, as shown in Fig. 3 (A to C) and Tables 4-6 below. # p < 0.05 compared with Control group; * p <0.05 compared with LPS group.
[0051] Table 4: leukocytes infiltration response after intraperitoneal injection Group leukocytes infiltration (105) Control 0.14 0.06 LPS 3.29 1.95#
CC mycelia 0.46 0.34*
DEX 0.56 0.29*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.46 0.34*
DEX 0.56 0.29*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0052] Table 5: phagocytes infiltration response after intraperitoneal injection Group phagocytes infiltration (105) Control 0.07 0.03 LPS 1.62 0.67#
CC mycelia 0.25 0.14*
DEX 0.27 0.26*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.25 0.14*
DEX 0.27 0.26*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0053] Table 6: Neutrophils infiltration response after intraperitoneal injection Group Neutrophils infiltration (105) Control 0.04 0.02 LPS 1.12 0.80#
CC mycelia 0.15 0.10*
DEX 0.16 0.16*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.15 0.10*
DEX 0.16 0.16*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0054] As shown in Fig. 4, oral administration of freeze-dried powder of Cordyceps cicadae mycelia active substance proved to be effective in improving inflammatory lung diseases. No significant changes were observed in the Control group with most alveolar structure remaining intact.
In the LPS group, pathological changes in the lung were clearly observed with the alveolar structure being damaged and fused. On the other hand, the lung diseases of the mice in the CC mycelia and DEX groups clearly improved.
In the LPS group, pathological changes in the lung were clearly observed with the alveolar structure being damaged and fused. On the other hand, the lung diseases of the mice in the CC mycelia and DEX groups clearly improved.
[0055] After oral administration, protein leakage response caused by endotoxin-induced lung inflammation was analyzed. It was found that freeze-dried powder of Cordyceps cicadae mycelia active substance was effective in reducing protein leakage response, as shown in Fig. 5 and Table 7 below. # p < 0.05 compared with Control group; * p <0.05 compared with LPS group.
[0056] Table 7: Protein leakage response after oral administration Group Protein leakage (mg/mL) Control 2.60 0.24 LPS 6.65 1.18#
CC mycelia 2.48 0.35*
DEX 3.11 0.64*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 2.48 0.35*
DEX 3.11 0.64*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0057] After oral administration, infiltration responses of (A) leukocytes (CD45) (B) phagocytes (CD45+/CD1 1 b+) and (C) neutrophils (CD45+/Ly6G+) caused by endotoxin-induced lung inflammation were analyzed. It was found that freeze-dried powder of Cordyceps cicadae mycelia active substance was effective in reducing infiltration responses of leukocytes, phagocytes and neutrophils, as shown in Fig. 6 (A to C) and Tables 8-10 below. # p < 0.05 compared with Control group; * p <0.05 compared with LPS group.
[0058] Table 8: leukocytes infiltration response after oral administration Group leukocytes infiltration (105) Control 0.38 0.22 LPS 3.17 0.82#
CC mycelia 0.70 0.46*
DEX 0.88 0.25*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.70 0.46*
DEX 0.88 0.25*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0059] Table 9: phagocytes infiltration response after oral administration Group phagocytes infiltration (105) Control 0.06 0.04 LPS 0.62 0.35#
CC mycelia 0.11 0.10*
DEX 0.08 0.05*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.11 0.10*
DEX 0.08 0.05*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0060] Table 10: Neutrophils infiltration response after oral administration Group Neutrophils infiltration (105) Control 0.02 0.01 LP S 0.29 0.09#
CC mycelia 0.04 0.02*
DEX 0.04 0.02*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
CC mycelia 0.04 0.02*
DEX 0.04 0.02*
(n=6) # Statistical significance compared to the Control group (p<0.05) * Statistical significance compared to the LPS group (p<0.05)
[0061] The Cordyceps cicadae mycelia active substance of the present invention have been proved through the above experiment to be effective in improving ALT.
Example 3: Preparing composition
Example 3: Preparing composition
[0062] The present invention provides a composition comprising a Cordyceps cicadae mycelia active substance to be prepared into a pharmaceutical composition as well as a health food.
[0063] The composition further includes an additive. In a preferred embodiment, the additive can be an excipient, preservative, diluent, filler, absorption enhancer, sweetener, lubricant, thickener or a combination thereof The excipient can be selected from sodium citrate, calcium carbonate, calcium phosphate, sucrose or a combination thereof. The preservative, such as benzyl alcohol, parabens, silicon or a combination thereof, can prolong the shelf life of pharmaceutical compositions. The diluent can be selected from water, ethanol, propylene glycol, glycerol or a combination thereof The filler can be selected from lactose, high molecular weight polyethylene glycol or a combination thereof. The absorption enhancer can be selected from dimethyl sulfoxide (DMSO), laurocapram, propylene glycol, glycerol, polyethylene glycol or a combination thereof The sweetener can be selected from Acesulfame K, aspartame, saccharin, sucralose, neotame or a combination thereof The lubricant can be selected from magnesium stearate or gum Arabic. The thickener can be cornstarch.
In addition to the additives listed above, other ones may be selected according to actual needs provided that the pharmaceutical effects of the composition are not affected.
In addition to the additives listed above, other ones may be selected according to actual needs provided that the pharmaceutical effects of the composition are not affected.
[0064] The composition can be developed into various products in the pharmaceutical industry. In a preferred embodiment, the composition is a drug, feed, drink, nutritional supplement, dairy product or health food.
[0065] The composition can take various forms to meet the subject's needs. In a preferred embodiment, the composition can be in powder, tablet, granule, suppository, microcapsule, ampoule/ampule, liquid spray or suppository form.
[0066] The composition of the present invention can be administered to an animal or a human. Provided that the effects of the composition are not affected, it can be made into any dosage forms and administered via an appropriate route to the animal or human depending on the dosage form.
[0067] When the Cordyceps cicadae mycelia active substance of the present invention is of dietary use, the form of the composition 1 as described below shall be an illustrative example of the Cordyceps cicadae mycelia active substance.
[0068] Composition 1: Freeze-dried powder of the Cordyceps cicadae mycelia active substance (20 wt%) was well-mixed with magnesium stearate used as a lubricant (8 wt%) and silicon used as a preservative (7 wt%). The resulting mixture was dissolved in pure water (65 wt%) and stored at 4 C
for future use. The notation "wt%" refers to the proportion of the weight of each ingredient relative to the total weight of the composition.
for future use. The notation "wt%" refers to the proportion of the weight of each ingredient relative to the total weight of the composition.
[0069] When the Cordyceps cicadae mycelia active substance of the present invention is of medical use in a liquid form, the form of the composition 2 as described below shall be an illustrative example of the Cordyceps cicadae mycelia active substance.
[0070] Composition 2: Freeze-dried powder of the Cordyceps cicadae mycelia active substance (20 wt%) was well-mixed with sucralose used as a sweetener (8 wt%), gum Arabic used as a lubricant (7 wt%) and sucrose used as an excipient (10 wt%). The resulting mixture was dissolved in pure water (55 wt%) and stored at 4 C for future use. The notation "wt%" refers to the proportion of the weight of each ingredient relative to the total weight of the composition.
[0071] These examples, though disclosed in the above description, do not intend to limit the present invention. A person ordinarily skilled in the art should be able to make appropriate changes to the features described therein with reference to the above teachings and still achieve the effects as claimed by the present application. Therefore, the scope of claims protecting the present invention shall be determined by the appended claims.
Claims (9)
1. Use of a Cordyceps cicadae mycelia for manufacturing a medicine for preventing and/or treating acute lung injury; wherein the medicine comprises a C'ordyceps cicadae mycelium fermentation liquid, a Cordyceps cicadae mycelium powder or a combination thereof, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, or a combination thereof.
2. The use of claim 1, wherein said medicine for treating acute lung injury is for alleviation of pathological symptoms of lung inflammation of a subject taking said medicine compared to that of a subject not taking said medicine.
3. The use of claim 2, wherein said medicine for treating acute lung injury is for restoration of integrity of damaged or fused alveoli of the subject taking said medicine.
4. The use of claim 1, wherein said medicine for treating acute lung injury is for reduction of protein leakage response of a subject taking said medicine compared to that of a subject not taking said medicine.
5. The use of claim 1, wherein said medicine for treating acute lung injury is for reduction of level of infiltration in inflamed cells of a subject taking said medicine compared to that of a subject not taking said medicine.
6. The use of claim 5, wherein said inflamed cells comprise leukocytes, phagocytes and/or neutrophils.
7. The use of any one of claims 1 to 6, wherein the medicine is prepared by a method comprising the following steps:
(a) culturing a Cordyceps cicadae mycelia in a plate medium between 15 and 30 C for 1 to 2 weeks;
(b) inoculating the Cordyceps cicadae mycelia of step (a) to a flask and culturing the mycelia between 15 and 30 C and at a pH of 2 to 6 for Date Recue/Date Received 2021-09-30 3 to 14 days; and (c) inoculating the Cordyceps cicadae mycelia of step (b) to a fermenter tank and culturing the mycelia by stirring between 15 and 30 C at a pH of 2 to 6 for 3 to 21 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid.
(a) culturing a Cordyceps cicadae mycelia in a plate medium between 15 and 30 C for 1 to 2 weeks;
(b) inoculating the Cordyceps cicadae mycelia of step (a) to a flask and culturing the mycelia between 15 and 30 C and at a pH of 2 to 6 for Date Recue/Date Received 2021-09-30 3 to 14 days; and (c) inoculating the Cordyceps cicadae mycelia of step (b) to a fermenter tank and culturing the mycelia by stirring between 15 and 30 C at a pH of 2 to 6 for 3 to 21 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid.
8. The use of claim 7, wherein the method further comprises steps of (d):
freeze-drying the Cordyceps cicadae mycelium fermentation liquid to obtain a freeze-dried product and grinding the freeze-dried product, so as to obtain a Cordyceps cicadae mycelium powder.
freeze-drying the Cordyceps cicadae mycelium fermentation liquid to obtain a freeze-dried product and grinding the freeze-dried product, so as to obtain a Cordyceps cicadae mycelium powder.
9. The use of claim 7 or 8, wherein air or a gas is further fed into the fermenter tank of step (c), and the gas comprises oxygen, carbon dioxide, helium or a combination thereof; pressure of the fermenter tank is 0.5 to 1.0 kg/cm2, and air flow rate or gas flow rate is 0.01 to 1.5 VVM.
Date Recue/Date Received 2021-09-30
Date Recue/Date Received 2021-09-30
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107147041A TWI701335B (en) | 2018-12-25 | 2018-12-25 | Method of manufacturing and the use of cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury |
TW107147041 | 2018-12-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3040916A1 CA3040916A1 (en) | 2020-06-25 |
CA3040916C true CA3040916C (en) | 2023-01-24 |
Family
ID=71141391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3040916A Active CA3040916C (en) | 2018-12-25 | 2019-04-23 | Method of manufacturing and the use of cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6789339B2 (en) |
KR (1) | KR102223608B1 (en) |
CN (1) | CN111434342B (en) |
CA (1) | CA3040916C (en) |
TW (1) | TWI701335B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111996129B (en) * | 2020-09-07 | 2022-06-17 | 广东省微生物研究所(广东省微生物分析检测中心) | New strain of cicada fungus and its use in anti-tumor and bacteriostasis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9733698A (en) * | 1997-10-24 | 1999-05-17 | Institute Of Materia Medica Chinese Academy Of Medical Sciences | Process for making and uses of cordyceps fermentation products |
TW201136599A (en) * | 2010-04-29 | 2011-11-01 | Grape King Inc | Active substance of Cordyceps sobolifera for curing or preventing diabetes and complications thereof, preparing method, and application thereof |
CN102240301B (en) * | 2010-05-14 | 2015-07-15 | 浙江泛亚生物医药股份有限公司 | Single-composition traditional Chinese medicine preparation, and preparation method and application thereof |
CN102242154B (en) * | 2010-05-14 | 2014-07-02 | 浙江泛亚生物医药股份有限公司 | Liquid fermentation method for producing paecilomyces cicadae mycelia and application of culture product |
CN103349286B (en) * | 2010-05-14 | 2015-12-23 | 浙江泛亚生物医药股份有限公司 | A kind of purposes of tunning of Paecilomyces cicadae |
HK1146565A2 (en) * | 2011-02-22 | 2011-06-17 | Shanghai Bioasia Life Technology Co Ltd | Chinese herbal health products and the preparation method and application thereof |
CN104672339B (en) * | 2015-02-03 | 2017-01-18 | 浙江省林业科学研究院 | Cordyceps cicadae rhzomorph as well as preparation method and application thereof |
CN106265768B (en) * | 2015-06-04 | 2019-12-31 | 葡萄王生技股份有限公司 | Cordyceps cicadae active substance, preparation method thereof, pharmaceutical composition containing cordyceps cicadae active substance and application of cordyceps cicadae active substance |
CN105567570B (en) * | 2015-12-23 | 2021-07-06 | 中华全国供销合作总社南京野生植物综合利用研究所 | Cordyceps cicadae mycelium and exopolysaccharide liquid fermentation production method |
TWI666324B (en) * | 2016-10-26 | 2019-07-21 | 葡萄王生技股份有限公司 | Cicada flower active substance and its use for reducing intraocular pressure |
CN108721340A (en) * | 2017-04-20 | 2018-11-02 | 威海昊同医药科技有限公司 | A kind of single-composition Chinese medicine preparation and its preparation method and application |
CN108315266B (en) * | 2018-03-06 | 2020-06-30 | 杭州师范大学 | Paecilomyces cicadae and application thereof |
-
2018
- 2018-12-25 TW TW107147041A patent/TWI701335B/en active
-
2019
- 2019-03-20 CN CN201910211121.3A patent/CN111434342B/en active Active
- 2019-03-27 JP JP2019061068A patent/JP6789339B2/en active Active
- 2019-04-12 KR KR1020190043253A patent/KR102223608B1/en active IP Right Grant
- 2019-04-23 CA CA3040916A patent/CA3040916C/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20200080100A (en) | 2020-07-06 |
CN111434342B (en) | 2022-04-15 |
JP6789339B2 (en) | 2020-11-25 |
TWI701335B (en) | 2020-08-11 |
JP2020105159A (en) | 2020-07-09 |
KR102223608B1 (en) | 2021-03-08 |
TW202024331A (en) | 2020-07-01 |
CN111434342A (en) | 2020-07-21 |
CA3040916A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Gut microbiota-dependent catabolites of tryptophan play a predominant role in the protective effects of turmeric polysaccharides against DSS-induced ulcerative colitis | |
KR101710091B1 (en) | Pharmaceutical composition for prevention or treatment inflammatory diseases comprising Siraitia grosvenori extract or fractions thereof, or compounds isolated from therefrom | |
CN117070426B (en) | Probiotic agent for improving alcoholic fatty liver disease and application thereof | |
KR100994444B1 (en) | Polysaccharide extracted from above ground part of astragalus membranaceus and pharmaceutical composition comprising the same | |
WO2023142877A1 (en) | Use of bacteroides fragilis in improvement and treatment of diarrhea | |
JP2020516699A (en) | Tumor Chemotherapy Microbial Agents to Prevent Enterotoxicity | |
KR20140116282A (en) | Compositions for Prevention and Treatment of Gastro-Intestinal Diseases Comprising Extract of fermented Curcuma longa L. | |
CA3040916C (en) | Method of manufacturing and the use of cordyceps cicadae mycelia active substance for preventing and/or improving acute lung injury | |
CN117100768A (en) | Use of akkermansia muciniphila (Akkermansia muciniphila) for improving and treating diarrhea | |
KR20190043996A (en) | Composition for prevention or treatment respiratory diseases comprising Chrysanthemum morifolium Ramatuelle extract and Scutellaria baicalensis extract as an active ingredient | |
JP4556009B2 (en) | Anti-inflammatory agents, preventive or ameliorating agents for allergic diseases and functional foods | |
CN1259041C (en) | Bromhexine Hydrochloride aseptic freeze-drying formulation for injection and its preparation method | |
CN114917254B (en) | Application of bacteroides fragilis in preparation of medicines for treating oral mucosa diseases | |
TWI723368B (en) | Method for manufacturing and the use of paecilomyces hepiali mycelia active substance for preventing and/or ameliorating acute lung injury | |
US10744197B2 (en) | Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration | |
EP3928785B1 (en) | Medicament and food for use in preventing or treating novel coronavirus pneumonia covid-19 | |
CN108853026A (en) | A kind of andrographolide for animals is scattered | |
TWI774903B (en) | Method for manufacturing and the use of lignosus rhinocerus mycelia active substance for preventing and/or ameliorating lung injury | |
JP2013055945A (en) | Oral inactivated vaccine and method for providing the same | |
WO2012067322A1 (en) | Pharmaceutical composition for treatment of asthma containing 4-phenylbutyric acids or pharmaceutically acceptable salts thereof as active ingredient | |
WO2024188199A1 (en) | Isolated christensenella, composition comprising same, and use | |
CN115120622A (en) | Application of ganoderma applanatum ethanol extract in relieving salmonella infection | |
WO2023037247A1 (en) | Compositions comprising bacillus amyloliquefaciens for preventing and treating ulcerative colitis | |
EP4144363A1 (en) | Drug, food and application of anti-coronavirus infection | |
JPH0678756A (en) | Microorganism capable of producing lps, lps and medicine and animal medicine containing lps |